Immunotherapy for Ovarian Cancer - Advanced Cancer Care

Overview of Immunotherapy for Ovarian Cancer

What is Immunotherapy for Ovarian Cancer?

Immunotherapy utilizes the immune system to specifically target ovarian cancer cells. This is primarily achieved through checkpoint inhibitors that block PD-1/PD-L1 pathways, which tumors use to evade detection. Unlike chemotherapy, immunotherapy activates T-cells to attack tumor antigens in cases of platinum-resistant or microsatellite unstable (MSI-high) ovarian cancers. It has shown promise in clinical trials for high-grade serous and endometrioid subtypes.

Types of Immunotherapy for Ovarian Cancer

• •Checkpoint Inhibitors (e.g., Pembrolizumab, Nivolumab)
  These PD-1/PD-L1 blockers have been approved for treating MSI-high or tumor mutational burden (TMB)-high ovarian cancers, with response rates of 10-15% in resistant cases.
• •Combination Immunotherapy
  This approach combines PD-1 inhibitors with PARP inhibitors, bevacizumab, or low-dose chemotherapy to enhance the 'hot' tumor microenvironments.
• •Experimental Approaches
  This includes CAR-T cell therapy targeting folate receptor-alpha, tumor-infiltrating lymphocyte (TIL) therapy, and vaccines currently in phase I/II trials.

When is Immunotherapy Needed?

• •For Platinum-Resistant Recurrence
  Single-agent checkpoint inhibitors offer benefits to 10-20% of heavily pretreated patients, particularly those with MSI-high endometrioid or clear cell cancers.
• •Combined with Standard Therapies
  Frontline trials are exploring combinations of PD-1 inhibitors with PARP maintenance therapy or bevacizumab, doubling the clinical benefit rates in homologous recombination deficiency (HRD)-positive tumors.
• •For Rare Molecular Subsets
  Tumors that are MSI-high (5-10% in endometrioid cases), TMB-high, or POLE-mutated respond best to immunotherapy. Patients with Lynch syndrome qualify for treatment through universal screening.

Treatment Process

Immunotherapy is typically administered through IV infusion every 3-6 weeks for 30-60 minutes in outpatient settings, continuing until disease progression or a maximum of 2 years. Baseline tumor sequencing helps identify potential responders. To prevent infusion reactions, steroids are administered as premedication, and monthly thyroid/adrenal function tests monitor immune-related adverse events. It’s important to note that radiographic responses may take 3-6 months to become evident due to pseudoprogression.

Benefits and Risks

Benefits of Immunotherapy for Ovarian Cancer:

Get Your Free Cancer Diet Plan & Report Analysis Now on WhatsApp

Talk to experts. Understand your reports. Get a personalized diet plan — all free to start.

Get My Free Plan on WhatsApp

India's First Cancer Care Management Platform

Free to start•Secure & private•No app download needed

Durable responses are possible, with 30-50% progression-free survival at one year for MSI-high cases, which outperform chemotherapy in resistant disease. Combination therapies demonstrate an overall response rate (ORR) of 15-40% compared to 5-10% in historical controls. The non-overlapping toxicities allow for potentially lifelong administration of treatment.

Side Effects and Risks:

Immune-related adverse events occur in 20-30% of patients, including colitis (with grade 3+ in 5%), pneumonitis (3%), and endocrinopathies such as hypothyroidism in 15% of cases. These may require steroids or immunosuppressants. Common side effects include fatigue and rash, though rare fatal events occur in less than 1% of patients.

Aftercare and Recovery

Caring for Yourself After Immunotherapy for Ovarian Cancer:

It is crucial to report any symptoms such as diarrhea, cough, or rash immediately. Annual thyroid screening will continue for life, and patients should avoid live vaccines. Staying hydrated and taking probiotics can help mitigate colitis. Quarterly scans will be necessary to monitor delayed responses, and good nutrition supports health during steroid tapering.

Why Choose Everhope

Everhope Oncology provides comprehensive molecular profiling to identify candidates for immunotherapy, onsite infusion services with rapid management of immune-related adverse events (irAEs), and nutritional support to prevent treatment interruptions.